Phathom Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 6.22 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 494.06M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-eros...